A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
NCT07423546
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. [18F]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by [18F]DOPA Kicer ([18F]DOPA relative uptake rate)).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SCHIZOPHRENIA 1 (Disorder)
- Schizoaffecitve Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- New York State Psychiatric Institute
- Last updated on ClinicalTrials.gov
- July 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- New York State Psychiatric Institute · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.